MedTrace Logo

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NCT03833700 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-02-27

No results posted yet for this study

Summary

This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Conditions

  • Solid Neoplasms
  • Colorectal Neoplasms
  • Gastrointestinal Tumors

Interventions

DRUG

E7386

E7386 doses.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833700 on ClinicalTrials.gov